Recommendations for diagnostics and therapy of gastrointestinal stromal tumors (GIST) in 2010
Journal Title: OncoReview - Year 2011, Vol 1, Issue 1
Abstract
Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors of gastrointestinal tract. Advances in the understanding of the molecular mechanisms of GIST pathogenesis have resulted for last years in the emerging of GIST as a distinct sarcoma entity. The paper describes guidelines for diagnostics and therapy of these tumors based on scientific basis and experts’ experience, which are commonly accepted and worth to recommend. Overexpression of KIT receptor, as a consequence of mutation of protooncogene KIT, is highly specific for GIST and enable for detection by immunohistochemistry staining (CD117) in tumor specimens. It is the most important criterion in microscopic diagnostics and indications for treatment with small-molecule tyrosine kinas inhibitors. Sending material for molecular analysis is strongly recommended (for KIT and PDGFRA genotyping). Radical surgery is still the mainstay treatment for primary, localized, resectable GISTs, although high percentages of the patients after potentially curative operations develop recurrent or metastatic disease. In inoperable/metastatic lesions the treatment of choice is tyrosine kinase inhibitor – imatynib mesylate – the first effective systemic therapy in advanced CD117(+) GIST. Recommended initial dose should be 400 mg daily (800 mg for exon 9 KIT mutants). Monitoring of the therapy should be based on serial computed tomography imaging of abdominal cavity with the assessment of changes of tumor size and density. In case of disease progression the increase of imatynib dose to 800 mg daily is recommended and if further progression exists – sunitinib in the initial dose 50 mg daily should be introduced. Clinical trials evaluating the role of surgery in combination of imatynib and the efficacy of other molecular targeted drugs in resistant cases are ongoing. Existing data indicate beneficial role of adjuvant imatynib therapy in terms of relapse-free survival, especially in group of patients with significant risk of relapse.. Presented recommendations for diagnostics and therapy of GIST should be practically implemented by physicians involved in management of GIST patients in Poland. The including GIST cases in national Clinical Registry (http://gist.coi.waw.pl) and standard treatment of patients in multidisciplinary team with expertise in GIST therapy, as well as enrollment of new cases to prospective clinical trials, are recommended.
Authors and Affiliations
Piotr Rutkowski
Keywords
Related Articles
- EP ID EP53084
- DOI -
- Views 253
- Downloads 0
Imaging techniques used to detect oncological treatment complications
Oncological drugs are toxic for the cardiovascular system, directly affecting cardiac function and anatomy. Oncological treatment complications may thus take the form of asymptomatic myocardial dysfunction, overt heart f...
Paraneoplastic neurological syndrome in the course of breast cancer
Paraneoplastic neurological syndromes (PNS) are a group of rarely observed disorders, accompanying about 1% of cancer diseases. They have a typically aggressive course, leading to profound and essentially irreversible di...
Follicular mucinosis on the forehead of a 15-year-old girl
Follicular mucinosis is a rare dermatosis characterized by accumulation of mucin in the follicular epithelium and sebaceous glands. Clinically, it is characterized by the presence of papules or well-circumscribed and inf...
Rehabilitation of patients with cancer of the respiratory system
Many patients with lung cancer have concomitant chronic obstructive pulmonary disease and heart diseases. The planned anticancer therapy should be individualized in relationship of patient’s cardiac and pulmonary conditi...
Depresja u osób z chorobą nowotworową. Rozpoznawanie i leczenie – aspekty praktyczne
Współwystępowanie depresji oraz choroby nowotworowej jest stanem częstym, choć współczynniki współistnienia obu chorób różnią się w zależności od takich czynników jak umiejscowienie nowotworu oraz faza choroby nowotworow...